Drug Trial Radar · NCT04670809
Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies
Last checked: Nov 20, 2026Latest source record: Dec 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
262
Planned (sponsor's estimate)
Start
Jul 27, 2020
Primary completion
Aug 2021
Study completion Dec 2021
Sponsor
- Lead sponsor
- Nanjing Yoko Biomedical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine the efficacy and safety of clevidipine for treating Hypertensive emergencies(defined as systolic blood pressure \>180 mmHg and/or diastolic blood pressure \>120 mmHg, accompanied by acute organ damage).
Conditions
- Hypertensive Emergency
Interventions
Clevidipine Butyrate InjectionDrug
Initiate the intravenous infusion of Clevidipine Butyrate Injection at 2 mg/hour. The dose should be doubled every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 32 mg/hour. The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
Ncardipine Hydrochloride InjectionDrug
Dilute the Ncardipine Hydrochloride Injection to 0.1mg/ml. Initiate the intravenous infusion at 0.5μg/(kg•min). A 0.5-1μg/(kg•min) dose should be added every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 6μg/(kg•min). The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Target reaching rate within 30 minTime frame: 30 min
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Anzhen Hospital,Capital Medical University
Beijing, China · Active not recruiting
Beijing Chao-Yang Hospital, Capital Medical University
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.